List of Therapeutic Companies in Utah - 27

Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2024, we have provided over 180 million units of essential medicines to hospitals, enough to help treat over 80 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for a pack of five pre-filled pens, regardless of insurance status. WHY CIVICA? Because patients should have the essential medicines they need when they need them. As a rapidly growing, entrepreneurial, nonprofit generic drug company our mission is to ensure quality generic medicines are accessible and affordable to everyone.

Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The company has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson’s; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company’s products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is based in Salt Lake City, Utah.

Curza is a small molecule therapeutics development company. Curza has developed a new class of antibiotics that are active and selective against Gram-negative pathogens.

DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.

Eris Biotech is a biotech company that develops drugs that only activate under low oxygen (hypoxic) environments. These drugs are referred to as hypoxia-activated prodrugs or HAPs. Their innovative treatments specifically target the tumor microenvironment, ensuring maximum effectiveness.

Our Vision: To revolutionize the structural heart market with new material, design and manufacturing technology expanding patient access, improving product performance and significantly reducing costs.

Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.

iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing non-surgical, non-invasive, pharmacologic innovations.

JSK’s Therapeutics’ mission is to aggressively develop JSK to treat multiple types of cancer. We seek to position JSK as a leader in the evolving field of NO therapeutics for cancer treatment and co-therapeutic use as appropriate.

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company’s pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

NuView Life Sciences is a clinical stage precision oncology company. The Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor is over-expressed on the surface of a wide range of cancer types at the onset of oncogenesis. NuView's NV-VPAC1 small molecule binding agent designed to identify and bind to the VPAC receptors has been utilized in clinical trials for binary in vitro and in vivo of confirmation of cancer. The NV-VPAC1 agent can be utilized to deliver existing therapeutics and new alpha and beta emitters. NuView will pair existing imaging and therapeutic radionuclides with NuViews proprietary agent and provide a Theranostics solution for patients and clinicians.

Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant challenges of male infertility. We recognize the critical gap in male fertility treatment and are committed to helping people on their path to parenthood. Our innovative in-vitro spermatogenesis (IVS) technology is poised to transform the fertility landscape, offering new hope and innovative solutions to those struggling to conceive. Led by a team of world-renowned scientists and physicians, we are advancing research into clinical applications. Our mission is to make parenthood a reality for more families through ethical, scientifically advanced fertility solutions. Did you know? *1 in 8 couples struggle with infertility. *50% of in vitro fertilization (IVF) procedures fail. *50% of infertility is linked to men. *Male infertility treatment has been stagnant since 1992. Paterna is the first to develop a truly new treatment for male infertility since then. With a strong foundation in science and a commitment to innovation, Paterna BioSciences is uniquely positioned to lead the next generation of male fertility treatments. We are actively seeking funding to accelerate our clinical development and commercialization efforts, bringing our life-changing technology to families worldwide. We help make parenthood possible. Learn more at www.PaternaBio.com Contact us: info@paternabio.com A New Paradigm in Human Reproduction.

Over the course of millions of years, nature evolved to create the world’s most awe-inspiring, life-changing health outcomes. Peel Therapeutics translates these evolutionary outliers to develop medicines for patients with cancer and inflammatory diseases. Using scientific and medical expertise, state-of-the-art technology and drug development knowledge, we redesign what nature offers into medicines for patients by tackling solubility, scalability, and bioavailability. Our clinical stage therapeutic pipeline treats a spectrum of devastating conditions, with a near-term focus on cancer and inflammation. At Peel Therapeutics, we push the limits of biology to develop highly effective and safe medicines for patients that transcend the incremental.

Phoenix PharmaLabs, Inc. (PPL) is a privately held preclinical drug discovery company focusing on the development and commercialization of new non-addictive treatments for pain and new therapies for the treatment of opiate addiction. PPL was founded in 2002 with the mission of bringing its new class of opioid pain therapies and addiction treatment to market. PPL has designed a novel family of ligands with high binding affinity at all three opiate receptors: mu, kappa and delta. These unique ligands, derived from opioid backbones using proprietary technology, have more balanced receptor activity than morphine and other opioids, with partial agonist / antagonist activity at mu, relatively higher, but not full, kappa agonist activity, and moderate delta activity. This profile results in first-ever opiate analgesics that appear to be non-addicting and free of all significant dangerous side effects. Studies of the drugs have been conducted by prominent scientists at leading institutions including Virginia Commonwealth University (VCU), the University of Michigan, SRI International and Torrey Pines Institute for Molecular Studies. Study results in rodents and monkeys performed by the National Institutes of Health (NIH) and SRI International Laboratories demonstrated the following: • Robust analgesic potency (8x - 60x stronger than morphine) • No dangerous narcotic effects • No signs of respiratory depression - at over 150x dosage • No death from overdose - even at 350x dosage • No physical dependence in naive rodents • Little or no abuse potential in monkeys • No dysphoria in monkeys • No inhibition of GI transport in rodents - even at 350x dosage • No significant diuresis in rodents • Does not precipitate withdrawal in dependent monkeys Since the drugs do not precipitate withdrawal, they offer very promising use for addiction therapy as a preferred substitute for methadone and buprenorphine.

PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products. PolarityTE's first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA) for a chronic cutaneous ulcer indication. SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com.

Q Therapeutics is a biotechnology company based out of 417 S Wakara Way, Salt Lake City, UT, United States.

Rebel Medicine is developing the next generation of local anesthetics that control pain locally and mitigate the need for opioids after surgery. Opioids after surgery can lead to addiction, respiratory depression, nausea, constipation, and death. These opioid-related adverse events are associated with prolonged hospitalizations and increased cost of care. Rebel’s long-acting local anesthetics will provide significant value to the customer, patient, and society alike by preventing addiction and reducing the cost of care. Headquartered in Salt Lake City, our team draws on firsthand experiences with active lifestyles to understand the real-world need for effective, non-opioid pain management solutions. This perspective drives our commitment to creating innovative solutions that improve patient outcomes.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

RxCell is a biotechnology company that specializes in the development of advanced cell-based therapies for the treatment of various diseases and medical conditions.

At Scientia Vascular, we believe that without access, therapy can not exist. Through cutting-edge innovation, we're answering our calling to radically disrupt the way diseases of the brain are treated. Our teams have been at the forefront of neurovascular systems, pushing beyond established boundaries to deliver the products physicians and patients need most.

Scintillant Bioscience provides in vitro biology services for therapeutics discovery and preclinical development for all therapeutic modalities. We help clients with all aspects of drug discovery projects, including screening, hit-to-lead, lead optimization, and preclinical development. We develop, validate and implement cell-based assays, typically for high content imaging (HCI)/high content screening (HCS)/high content analysis (HCA) and other forms of automated microscopy, including time-lapse imaging. Additionally we provide a variety of other services, such as plate-reader assays, proteomics, molecular biology services and more. We are happy to work with you on any of your needs for biochemical or cell-based assay development, validation or implementation. We have developed drug-discovery assays using primary cells, cell lines and iPSC-derived cell types. We will custom build stably overexpressing-, mutant- or reporter-gene cell lines as required for your drug-discovery programs. Let us help with your drug-discovery challenges.

Second Heart Assist Inc. is a medtech startup company that will revolutionize the treatment of chronic heart failure (HF). With its novel aortic stent pump technologies, Second Heart will enhance the lives of millions who suffer from chronic HF worldwide.

Sethera is redefining the field of peptide therapeutics with a unique platform that integrates AI, mRNA display, and phage display technologies. We create extensive libraries of constrained peptides, providing unparalleled screening capabilities for drug discovery. Our mission is to accelerate the development of innovative therapies, partnering with industry leaders to bring groundbreaking treatments to market.

Spriaso is a biopharmaceutical company dedicated to improving therapeutics through innovative patient friendly product options. Spriaso has several candidates in development with a focus on the central nervous system (CNS) and gastrointestinal (GI) disorders. Our portfolio of unique products have successfully completed proof of principle clinical studies. In addition, Spriaso develops ANDA products and has received an FDA approved NDA. These products are available for out-license to a marketing partner and are protected by multiple issued and pending patents.

SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.

Thunder Biotech, Inc. is an immune-oncology company developing patented MOTO-CAR™ technology - genetically engineered CAR macrophages - that help cancer patients' immune cells recognize and attack solid tumors. Traditional cancer treatments— like surgery, radiation, and chemotherapy—are often ineffective, invasive, and difficult to tolerate. Thunder Biotech is designing MOTO-CAR™s to be a more effective and humane therapy. Thunder Biotech's MOTO-CAR™s re-educate Tumor Associated Macrophages and restore their M1 ability to recognize and eliminate tumor cells. In addition, MOTO-CAR™s are armed with tumor specific receptors that directly adhere to the tumor cell surface allowing them to initiate tumor cell destruction and recruit the natural T cell response engaging them to eliminate the tumor. This T cell response will then provide the body with a memory response preventing tumor recurrence.

TikkunLev Therapeutics is on a mission to revolutionize the treatment of heart failure by targeting the underlying biology of failing heart muscle. Founded on the pioneering research of Professor Robin Shaw M.D., Ph.D., our lead program, TLT-101, is a precision therapy that targets the underlying protein trafficking defects in heart failure. Extensive preclinical data demonstrate an unprecedented efficacy and safety profile with our therapeutic approach. TLT-101 is in IND-enabling development for non-ischemic dilated cardiomyopathy (DCM), a severe and progressive disease that is a leading cause of heart failure. With cardiovascular disease remaining the leading global cause of death and 1 in 4 people expected to develop heart failure, our innovative approach aims to repair the heart and transform lives.